Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of 5-grass mix SLIT-drops in adults with grass pollen-induced rhinoconjunctivitis
2020-000455-12Phase 3Completed
- Sponsor
- ALK-Abelló
- Start
- Dec 2020
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and grass pollen allergy comparing 5-grass mix SLIT-drops with Placebo (2 arms). Primary endpoint: Average daily allergic rhinoconjunctivitis total combined score during the 2nd peak grass pollen season. Started Dec 2020; status: completed.
02
Drugs
standardised 5-grass pollen allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)grass pollen allergy
Beyond the preview
Go deeper on 2020-000455-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000455-12.